Shire’s decision was based on a study that compared their existing CLD workflow to a workflow using the Beacon.
| |
| [30-January-2018] |
| EMERYVILLE, Calif., Jan. 30, 2018 /PRNewswire/ -- Berkeley Lights, Inc. (BLI), a leader in digital cell biology, announced today that Shire has purchased the Beacon platform to accelerate their cell line development (CLD) process. Shire’s decision was based on a study that compared their existing CLD workflow to a workflow using the Beacon. Based on the pilot study, the Beacon platform was able to quickly and efficiently identify target secreting clones which saved resources while also accelerating the discovery and development process. The four modules of Berkeley Lights’ Beacon platform - import, culture, assay, and export - can be applied for cell line development, antibody discovery and engineering, gene editing, and research. Automating workflows using the precise individual cell manipulation capabilities of the Beacon platform increases efficiencies and reduces overall time while providing insights into the behavior of clonal populations not possible using traditional techniques. Beacon is capable of screening thousands of clones in less than a week. “We are very excited to support Shire by helping them increase the scale and precision of their cell line development process to innovate faster,” said, Eric Hobbs, PhD, CEO at Berkeley Lights, Inc. “At Berkeley Lights, our mission is to deliver versatile platforms that combine biology, technology and information, enabling our customers to automate manual lab workflows and focus on the hard science.” To learn more about the Beacon Cell Line Development (CLD) Workflow, visit https://www.berkeleylights.com/beacon-applications/cell-line-development/. About Berkeley Lights: ??Berkeley Lights, Inc. (BLI) develops and commercializes platforms on which many bio-pharmaceutical, genomic, and cellular therapy applications will run. BLI launched its first commercial platform, the Beacon*, in December 2016. The Beacon platform is ideally suited for cell line development and direct B-cell (plasma and memory cells) antibody discovery workflows. The flexibility and precision of the Beacon platform allows users to automate biological processes with single cell resolution. BLI is continuously developing new applications to align with its partners’ requirements. BLI’s technologies make it possible for customers to accelerate learning and dramatically improve workflows. * For Research Use Only. Not for use in diagnostic procedures. For more information, visit http://www.berkeleylights.com/.
View original content with multimedia:http://www.prnewswire.com/news-releases/shire-adopts-berkeley-lights-beacon-optofluidic-platform-to-speed-cell-line-development-300589756.html SOURCE Berkeley Lights, Inc. |
